-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The LY03012 declaration of astronomy is the treatment of chronic pain such as peripheral nerve pain, fibromyalgia and osteoarthritis.
The Phase I study, using randomized, double-blind, placebo-controlled, single and multiple dose increments, was designed to assess the safety, toerability and PK characteristics of healthy subjects after taking LY030112, 60 subjects participated in a single drug study (phase I), 48 subjects entered one daily and took multiple drug studies for 7 consecutive days (phase II).
results showed that healthy subjects took 80 to 400 mg a day for 80 to 320 mg for 7 days after the overall safety, tolerance is good, the common adverse events are mainly nausea, vomiting, drowsiness and so on.
adverse events were mostly mild, a small number were moderate, all had good prognosmation, no subjects withdrew from the study due to adverse events, and no unannored adverse events occurred.
Excessive sedation and drowsiness has always been a defect in chronic pain treatment, seriously affecting work and life, such as driving, mechanical operation, and most social activities, including communication, but also lead to the dose of medication can not be further improved, so can not achieve better results, is the current clinical treatment of chronic pain is an important reason for the lack of effectiveness.
IQIVA data, analgesants reached 15.82 billion yuan in China in 2019, rising at a compound annual growth rate of 17.4% from 2017 to 2019.
analgesics such as buprenorphine patches and fentanyl patches from the Greenleafe Group are now available worldwide.
addition, a class 1 new drug LPM3480392 injection (LY03014) and other innovative analgesics are in the research stage.
content Source: Medical Rubik's Cube Info